Flossbach Von Storch AG Takes Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Flossbach Von Storch AG purchased a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,049 shares of the company’s stock, valued at approximately $1,692,000.

A number of other large investors also recently made changes to their positions in IDXX. Moneta Group Investment Advisors LLC lifted its stake in shares of IDEXX Laboratories by 121,647.2% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 7,447,279 shares of the company’s stock valued at $3,038,192,000 after purchasing an additional 7,441,162 shares during the period. Norges Bank bought a new stake in shares of IDEXX Laboratories in the 4th quarter valued at $336,416,000. International Assets Investment Management LLC increased its position in shares of IDEXX Laboratories by 51,631.3% in the 4th quarter. International Assets Investment Management LLC now owns 547,834 shares of the company’s stock valued at $304,075,000 after buying an additional 546,775 shares in the last quarter. Morgan Stanley increased its position in shares of IDEXX Laboratories by 36.0% in the 4th quarter. Morgan Stanley now owns 986,232 shares of the company’s stock valued at $402,344,000 after buying an additional 260,926 shares in the last quarter. Finally, Alliancebernstein L.P. increased its position in shares of IDEXX Laboratories by 6.4% in the 2nd quarter. Alliancebernstein L.P. now owns 3,592,832 shares of the company’s stock valued at $1,804,428,000 after buying an additional 214,529 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX traded up $2.07 during midday trading on Thursday, reaching $480.31. 52,087 shares of the company were exchanged, compared to its average volume of 422,514. The stock’s 50-day moving average price is $541.86 and its 200-day moving average price is $508.71. The stock has a market cap of $39.89 billion, a P/E ratio of 47.49, a PEG ratio of 3.77 and a beta of 1.26. IDEXX Laboratories, Inc. has a one year low of $372.50 and a one year high of $583.39. The company has a quick ratio of 1.17, a current ratio of 1.57 and a debt-to-equity ratio of 0.42.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, February 5th. The company reported $2.32 EPS for the quarter, topping analysts’ consensus estimates of $2.12 by $0.20. The company had revenue of $901.60 million for the quarter, compared to analyst estimates of $891.88 million. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. IDEXX Laboratories’s revenue was up 8.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.05 earnings per share. On average, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.15 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. JPMorgan Chase & Co. increased their target price on IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Piper Sandler downgraded shares of IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 target price for the company. in a research note on Tuesday, January 30th. The Goldman Sachs Group raised their target price on shares of IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a research note on Wednesday, January 17th. Barclays raised their price objective on shares of IDEXX Laboratories from $605.00 to $655.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Finally, William Blair restated an “outperform” rating on shares of IDEXX Laboratories in a research report on Tuesday, April 9th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $591.50.

Insider Activity at IDEXX Laboratories

In related news, SVP George Fennell sold 8,198 shares of the business’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $573.87, for a total value of $4,704,586.26. Following the transaction, the senior vice president now owns 6,712 shares in the company, valued at $3,851,815.44. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, SVP George Fennell sold 8,198 shares of the company’s stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the transaction, the senior vice president now owns 6,712 shares in the company, valued at $3,851,815.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jonathan Jay Mazelsky sold 12,000 shares of the company’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the transaction, the chief executive officer now owns 79,247 shares in the company, valued at approximately $45,377,624.67. The disclosure for this sale can be found here. Insiders have sold a total of 43,524 shares of company stock worth $24,871,960 over the last quarter. Company insiders own 2.11% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.